RE:RE:RE:RE:RE:Posted on LinkedIn Agree the VM would be pure hints like where pain is coming from or peripheral scan data --likely not much there. But the stem cell they highlighted precursor markers that were genetic I think. So if they have some biopsy data the contract organizations analysis would likely include those markers taken with every blood withdrawal. You may get some tiny dataset that either conforms to that poster they presented or shows it ain't so in humans. Maybe not statistically significant datasets, but hints those markers moved the right way or not. Seems plausable to me, but maybe would take a lot more time to get that kind of useful biopsy data. Doubt they'd share that granularity, but they could say something like the human data was along the lines of the pre-clinical CSC marker study. Marsolais's claiming a multi-modal MOA next week, so hopefully he has some inkling it's going that way in humans.